Showing results (751-760 of 1,410) with videos related to
Sort By:
Pageof 141
NPJ Parkinson'S Disease|March 30, 2023
A scoping review of neurodegenerative manifestations in explainable digital phenotypingHessa Alfalahi, Sofia B Dias, Ahsan H Khandoker, et al.NPJ Parkinson'S Disease|May 17, 2023
The genetic spectrum of a cohort of patients clinically diagnosed as Parkinson's disease in mainland ChinaYi-Min Sun, Xin-Yue Zhou, Xiao-Niu Liang, et al.NPJ Parkinson'S Disease|December 17, 2019
PINK1 phosphorylates ubiquitin predominantly in astrocytesSandeep K Barodia, Laura J McMeekin, Rose B Creed, et al.NPJ Parkinson'S Disease|December 12, 2018
Safety and tolerability of IRL790 in Parkinson's disease with levodopa-induced dyskinesia-a phase 1b trialPer Svenningsson, Anders Johansson, Dag Nyholm, et al.NPJ Parkinson'S Disease|November 28, 2018
Risk factors of levodopa-induced dyskinesia in Parkinson's disease: results from the PPMI cohortPaolo Eusebi, Michele Romoli, Federico Paolini Paoletti, et al.NPJ Parkinson'S Disease|November 28, 2018
24-hour levodopa-carbidopa intestinal gel may reduce troublesome dyskinesia in advanced Parkinson's diseaseBelinda Cruse, Hugo Morales-Briceño, Florence C F Chang, et al.NPJ Parkinson'S Disease|October 27, 2022
Laboratory prognostic factors for the long-term survival of multiple system atrophyJung Hwan Shin, Han-Joon Kim, Chan Young Lee, et al.NPJ Parkinson'S Disease|October 18, 2022
Druggable transcriptomic pathways revealed in Parkinson's patient-derived midbrain neuronsMark van den Hurk, Shong Lau, Maria C Marchetto, et al.NPJ Parkinson'S Disease|June 11, 2025
Lipid profiling of Parkinson's disease brain highlights disruption in Lysophosphatidylcholines, and triacylglycerol metabolismAli Yilmaz, Nadia Ashrafi, Romana Ashrafi, et al.NPJ Parkinson'S Disease|June 18, 2025
Modeling and optimizing deep brain stimulation to enhance gait in Parkinson's disease: personalized treatment with neurophysiological insightsHamid Fekri Azgomi, Kenneth H Louie, Jessica E Bath, et al.Pageof 141